News

According to reports, Pfizer is close to acquiring Metsera for $7.3 billion, with Metsera's stock soaring 50% in pre-market trading and Pfizer rising about 2%. The Financial Times reported that Pfizer is nearing a $7.3 billion acquisition of the weight loss drug company Metsera. Pfizer will pay Metsera $47.50 per share in cash, with an additional $22.50 per share contingent on achieving certain performance milestones, bringing the company's valuation to a maximum of $7.3 billion. This offer represents a premium of about 110% over Metsera's closing price of $33.32 last Friday. As one of the potential companies in the next generation of weight loss drugs, Metsera is competing for a weight loss drug market worth billions of dollars. Upon completion of the acquisition, Pfizer will gain Metsera's weight loss injection MET-233i, which helped patients lose up to 8.4% of their weight in just 36 days during early small-scale trials. Notably, compared to existing products from market leaders like Novo Nordisk (NVO.US) and Eli Lilly (LLY.US), MET-233i may allow for less frequent dosing, reducing patient injections from once a week to once a month, potentially differentiating it from existing therapies